Project

primary vs secondary resistance to EGFR-targeted therapy in colorectal cancer: biological and predictive significance of stromal-derived neuregulin-1

Code

365O2312

Duration

01 October 2011 → 30 September 2013

Funding

Funding by bilateral agreement (private and foundations)

Promotor

Olivier De Wever

Research disciplines

Medical and health sciences
- Public health care
- Public health sciences
- Public health services

Keywords

resistance colon cancer carcinoma-associated fibroblast tumor environment

Project description

Anti-EGFR therapy (cetuximab or panitumumab) is a well known targeted therapy in metastatic colorectal cancer (mCRC). This project will search for insights in stromal-dependent delivery of signalling ligands that are associated with upfront resistance to anti-EGFR therapy or mechanisms of acquired resistance to anti-EGFR therapy; and to find biomarkers identifying patients at high risk for therapy resistance.